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Estrogens have a protective effect on kidney fibrosis in
several animal models. Here, we tested the effect of
raloxifene, an estrogen receptor modulator, on the change in
serum creatinine or estimated glomerular filtration rate
(eGFR) and incident kidney-related adverse events. We
performed a post-hoc analysis of the multiple outcomes of
raloxifene evaluation trial, a double-masked, placebo-
controlled randomized clinical trial encompassing 7705 post-
menopausal women (aged 31–80 years) with osteoporosis.
Participants were randomized to either of two doses of
raloxifene, 60 or 120mg/day, or placebo. Serum creatinine
was measured at a central laboratory at baseline and
annually. Adverse events were assessed every 6 months and
uniformly categorized. Compared with those in the placebo
group, participants on raloxifene had a slower yearly rate of
increase in creatinine (significant at the low dose) and a
significantly slower yearly rate of decrease in eGFR for both
doses over 3 years of follow-up. Raloxifene was associated
with significantly fewer kidney-related adverse events
compared with placebo. Thus, treatment with raloxifene was
safe and renoprotective. Clinical trials of raloxifene in post-
menopausal women with kidney disease designed to look at
kidney outcomes are needed to confirm these findings.
Kidney International (2011) 79, 241–249; doi:10.1038/ki.2010.378;
published online 6 October 2010
KEYWORDS: randomized controlled trials; renal function decline; risk factors
Chronic kidney disease has recently emerged as a public
health concern.1 There are an estimated 15 million people
living with kidney disease stage 3,2 the majority of whom are
adults older than 65 years, and over 300,000 patients on
dialysis in the United States.3 Thus, current research is
focusing on identification of risk factors for progression of
chronic kidney disease. It is currently recognized that women
have a slower progression of non-diabetic kidney disease
compared with men.4 Population-based studies from the
United States and Norway have shown that women are less
likely to progress to end-stage renal disease compared with
men.5,6 However, an observational study of 5845 women in
Canada showed that hormone use was associated with a
significant loss of kidney function.7 At present, the mechan-
ism by which sex affects the progression rate of renal disease
is unknown, but there is evidence to support gender
differences in glomerular hemodynamics, renal size and
glomerular number.8
In addition, studies in animals support the concept that
testosterone is a promoter of renal scarring, whereas estrogen
reduces matrix deposition and scarring.9–11 Selective estrogen
receptor modulators (SERMs), such as raloxifene, activate the
estrogen receptor and function as estrogen agonists in some
tissues, such as bone and vascular tissues, and estrogen
antagonists in other tissues, such as breast and endome-
trium.12 In the kidney, animal data have suggested a
protective effect of SERMs similar to estrogens. In cultured
mesangial cells, estradiol and SERMs inhibit the generation
of types I and IV collagen, whereas testosterone has no
effect.13–15 In mouse models of diabetes, raloxifene reduces
kidney damage.16,17 In summary, epidemiological studies
have shown that women have a slower rate of kidney disease
progression compared with men, but that hormone therapy
may accelerate the loss of kidney function, and animal studies
suggest that female sex hormones may have beneficial effects.
We undertook this post-hoc analysis of the multiple outcomes
of raloxifene evaluation (MORE) trial to test the hypothesis
that raloxifene treatment in post-menopausal women with
osteoporosis is associated with a slower rise in serum
creatinine or fall in estimated glomerular filtration rate
(eGFR). Secondary analyses examined whether raloxifene
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treatment was associated with lower rates of kidney-related
adverse events and lower rates of proteinuria.
RESULTS
Participant characteristics
The three treatment groups were comparable at baseline with
the exception of the percentage of women taking anti-
diabetic medications and statins at baseline, which was
slightly higher in the 60mg/day raloxifene group and the rate
of those with eGFRo45ml/min per 1.73m2, which was lower
in those assigned to 60mg of raloxifene (Table 1). The mean
follow-up time and s.d. was 3.57 (0.99) years for the entire
study period, 2.61 (0.62) years for the core treatment phase of
0–3 years. The mean age of the participants was 66.0 years
with an s.d. of 7.0. Over 96% of the participants designated
themselves to be white. Hypertension was present in 55% of
the participants and 4% were diabetic. Half of the women
(49.8%) had serum estradiol levels below 1.4 pg/ml. The flow
of patients through the study is shown in Figure 1.
Comparison of the core treatment phase to the extension
phase
The effect of treatment on the change in serum creatinine
and eGFR was found to be significantly different between the
core treatment phase (0–3 years) and the extension phase in
year 4 (Po0.004). Therefore, all analyses will be limited to
the core treatment phase of 3 years of follow-up. The women
in our analysis subset who continued to the extension phase
(N¼ 5244) were generally healthier than those who did not
continue (N¼ 1689). They were significantly younger by a
mean of 1.5 years, less likely to be smokers, to have
hypertension or proteinuria, less likely to use angiotensin-
converting enzyme inhibitors, but were more likely to use
non-steroidal anti-inflammatory drugs, and have a lower
serum creatinine level at baseline (data not shown). Women
in the placebo group were less likely to continue on to the
extension (63.47%) compared with those on raloxifene
(67.47%, Po0.01). In addition, during year 4, bispho-
sphonates were used by 160 (8.33%) in the placebo group
and 193 (4.88%) of those on raloxifene (Po0.0001).
Reported compliance with taking the calcium and vitamin
D supplements decreased during the extension phase. The
rate of women reporting compliance for calcium and vitamin
D supplement use for the period of 2.5–3 years was 96.87 and
98.11%, respectively, but during the 3.5- to 4-year period the
rates dropped to 94.74 and 96.00% (Po0.0001).
Serum creatinine and eGFR
The random-effects model results indicate that for both
creatinine and eGFR there was no significant difference
Table 1 | Baseline characteristics of the 6933 post-menopausal women in the analysis subset
Characteristic
Placebo
(n=2323)
Raloxifene 60mg/day
(n=2288)
Raloxifene 120mg/day
(n=2322) P-valuea
Age (yrs), mean±s.d. 66.2±7.0 66.0±6.9 65.8±7.2 0.20
White race, n (%) 2250 (96.9) 2217 (96.9) 2237 (96.3) 0.50
Years since menopause, mean±s.d. 18.8±8.4 18.6±8.4 18.3±8.2 0.11
Diabetes mellitus, n (%) 85 (3.7) 100 (4.4) 79 (3.4) 0.21
Hypertension, n (%) 1287 (55.4) 1251 (54.7) 1264 (54.4) 0.79
ACE inhibitor use, n (%) 118 (5.1) 120 (5.2) 131 (5.6) 0.68
ARB use, n (%) 47 (2.0) 45 (2.0) 39 (1.7) 0.65
Statin use, n (%) 99 (4.3) 120 (5.2) 86 (3.7) 0.04
NSAID use, n (%) 1022 (44.0) 1002 (43.8) 1054 (45.4) 0.49
Diabetic medication use, n (%) 29 (1.3) 50 (2.2) 38 (1.6) 0.05
History of hysterectomy, n (%) 524 (22.6) 518 (22.6) 499 (21.5) 0.58
Smoking status, n (%)
Never 1369 (59.7) 1352 (59.7) 1350 (59.0) 0.95
Past 538 (23.5) 541 (23.9) 544 (23.8)
Current 385 (16.8) 371 (16.4) 394 (17.2)
Body mass index, kg/m2, mean±s.d. 25.3±4.0 25.3±4.0 25.3±4.0 0.99
Systolic BP, mmHg, mean±s.d. 133.5±19.2 133.5±18.8 133.0±18.8 0.66
Diastolic BP, mmHg, mean±s.d. 78.6±10.5 78.2±10.1 78.2±9.9 0.26
Total cholesterol, mg/dl, mean±s.d. 237.6±41.5 238.4±40.0 236.5±41.0 0.27
HDL cholesterol, mg/dl, mean±s.d. 60.5±14.7 60.1±14.8 60.2±15.3 0.52
Triglycerides, mg/dl, mean±s.d. 112.0±62.7 113.0±73.0 111.4±66.4 0.66
Hemoglobin A1C, %, mean±s.d. 6±1 6±1 6±1 0.29
Estradiol X1.4 pg/ml, n (%) 1163 (50.2) 1116 (49.0) 1162 (50.3) 0.61
eGFRo45ml/min per 1.73m2, n (%) 124 (5.34) 78 (3.41) 107 (4.61) o0.01
Serum creatinine, mg/dl, mean±s.d. 1.02±0.14 1.02±0.13 1.02±0.13 0.44
Proteinuria present, n (%) 66 (2.9) 54 (2.4) 52 (2.3) 0.93
Abbreviations: ACE inhibitor, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BP, blood pressure;eGFR, estimated glomerular filtration rate;
HDL, high density lipoprotein; NSAID, nonsteroidal anti-inflammatory drug.
To convert total and HDL cholesterol from mg/dl to mmol/l multiply by 0.0259. To convert triglycerides from mg/dl to mmol/l multiply by 0.0113. To convert estradiol to
pmol/l multiply by 3.671. To convert creatinine to mmol/l multiply by 88.4.
aP-values for continuous variables are from analysis of variance if normally distributed and Kruskal–Wallis test if skewed. P-values for categorical variables are from a w2-test.
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between raloxifene and placebo in baseline levels
(b-coefficient for treatment PX0.12) (first two columns, Tables
2 and 3). The effect of treatment with raloxifene at 60 or
120mg/day was very similar, as seen in the Figures 2a and 3a.
Overall, serum creatinine increased on average by 0.004mg/dl
per year (Po0.0001), with the women on raloxifene
increasing at a slower rate over time than those women in
the placebo group (60mg group P¼ 0.03, 120mg group
P¼ 0.11) (last two columns, Table 2, Figure 2). The 3-year
mean increase of serum creatinine based on this model was
0.01mg/dl for the placebo group, 0.0004mg/dl for those on
60mg of raloxifene, and 0.01mg/dl for those on 120mg of
raloxifene. eGFR decreased on average by 0.34ml/min per
1.73m2 per year (Po0.0001) (‘Time’ column, Table 3), with
the women on raloxifene decreasing at a slower rate over time
than those women in the placebo group (P¼ 0.03) (last two
columns, Table 3, Figure 3). The 3-year mean decrease of
eGFR based on this model was 0.98ml/min per 1.73m2 for
the placebo group, 0.56ml/min per 1.73m2 for those on
60mg of raloxifene, and 0.55ml/min per 1.73m2 for those on
120mg of raloxifene. There were no significant interactions
with treatment and diabetes, hypertension, or estradiol level.
Results were not substantially altered after further adjustment
for baseline diabetic medication use and statin use or
adjusting for blood pressure in a time-varying fashion.
Estimates of the interaction of time and treatment were
similar in magnitude, but lost statistical significance in
models adjusting for time-varying low-density lipoprotein
cholesterol or hemoglobin A1C, which may be due to the
reduced sample size. When including the extension phase in
the analysis, there was no significant difference between
raloxifene dose or placebo in either serum creatinine change
or eGFR decrease (PX0.88).
Secondary outcomes
A total of 28 (0.6%) participants in the raloxifene group and
29 women (1.1%) in the placebo group had an adverse event
related to kidney function, relative hazard (95% (confidence
interval) CI 0.50 (0.29–0.85) (Table 4). At baseline there was
no difference in the percentage of participants with
proteinuria between treatment groups (P¼ 0.39, Table 1).
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Figure 1 | Study recruitment and follow-up for kidney-specific
outcomes in the MORE trial.
Table 2 | Association between treatment with raloxifene and change in serum creatinine (mg/dl) over 3 years in 6933
participants of the MORE trial
Baseline comparison with placebo
Change
over time
Rate of change over time compared with placebo group
Analysis subgroup RLX 60 b RLX 120 b (years) b RLX60*time b RLX120*time b
All 0.006 0.006 0.004** 0.002* 0.002
Diabetics (n=265) 0.028 0.002 0.013 0.007 0.004
Non-diabetics (n=6631) 0.005 0.005 0.004** 0.002 0.002
P-interaction P=0.15
Hypertensives (n=3817) 0.011 0.007 0.006** 0.003 0.002
Non-hypertensives (n=3135) 0.001 0.004 0.001 0.002 0.002
P-interaction P=0.22
Probable kidney disease (n=1070) 0.057** 0.025 0.005 0.003 0.002
No kidney disease (n=5767) 0.005 o0.000 0.004** 0.002* 0.002
P-interaction Po0.001
Estradiol level o1.4 pg/ml (n=3464) 0.004 0.006 0.004** 0.002 0.001
Estradiol level X1.4 pg/ml (n=3442) 0.007 0.005 0.004** 0.003 0.002
P-interaction P=0.84
Abbreviations: MORE, multiple outcomes of raloxifene evaluation; RLX, raloxifene.
*Po0.05, **Po0.01.
To convert estradiol to pmol/l multiply by 3.671. To convert creatinine to mmol/l multiply by 88.4. Probable kidney disease defined as having one or more of the following:
estimated glomerular filtration rateo45ml/min per 1.73m2, diabetes mellitus, proteinuria, use of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker.
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Over the 3-year follow-up period, there was no significant
change in proteinuria prevalence over time (P¼ 0.86), and
no significant interaction with treatment and time (P¼ 0.21).
Participants with probable kidney disease
There were 1070 participants who were classified as having
probable kidney disease based on the presence of baseline
eGFRo45ml/min per 1.73m2, diabetes mellitus, proteinuria
Table 3 | Association between treatment with raloxifene and change in eGFR (ml/min per 1.73m2) over 3 years in 6933
participants of the MORE trial
Baseline comparison with placebo
Change over time
Rate of change over time compared with placebo group
Analysis subgroup RLX 60 b RLX 120 b (years) b RLX60*time b RLX120*time b
All 0.235 0.393 0.336** 0.145* 0.142*
Diabetics (n=265) 2.099 0.277 0.440 0.117 0.204
Non-diabetics (n=6631) 0.128 0.392 0.336** 0.143* 0.153*
P-interaction P=0.06
Hypertensives (n=3817) 0.450 0.382 0.419** 0.137 0.141
Non-hypertensives (n=3135) 0.055 0.360 0.239** 0.148 0.139
P-interaction P=0.52
Probable kidney disease (n=1070) 2.757** 1.171 0.159 0.075 0.015
No kidney disease (n=5767) 0.277 0.162 0.382** 0.195** 0.181**
P-interaction Po0.001
Estradiol level o1.4 pg/ml (n=3464) 0.150 0.527 0.374** 0.131 0.144
Estradiol level X1.4 pg/ml (n=3442) 0.260 0.234 0.298** 0.149 0.132
P-interaction P=0.66
Abbreviations: eGFR, estimated glomerular filtration rate; MORE, multiple outcomes of raloxifene evaluation; RLX, raloxifene.
To convert estradiol to pmol/l multiply by 3.671. Probable kidney disease defined as having one or more of the following: estimated glomerular filtration rateo45ml/min per
1.73m2, diabetes mellitus, proteinuria, use of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker.
*Po0.05, **Po0.01.
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Figure 2 |Creatinine change over 3 years in the MORE trial.
(a) A 3-year change over time in serum creatinine in 6933 post-
menopausal women participating in the MORE trial. (b) A 3-year
change over time in serum creatinine in 1070 post-menopausal
women with probable kidney disease (KD) and 5767 post-
menopausal women without kidney disease (no KD) in the MORE
trial. MORE, multiple outcomes of raloxifene evaluation.
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Figure 3 | Estimated glomerular filtration rate (eGFR) change
over 3 years in the MORE trial. (a) A 3-year change over time in
eGFR in 6933 post-menopausal women participating in the MORE
trial. (b) A 3-year change over time in eGFR in 1070
post-menopausal women with probable kidney disease (KD)
and 5767 post-menopausal women without kidney disease
(no KD) in the MORE trial. MORE, multiple outcomes of raloxifene
evaluation.
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or the use of angiotensin-converting enzyme inhibitors or
angiotensin receptor blockers. In this sub-group serum
creatinine was lower at baseline in the raloxifene 60mg
group. Although it did not reach statistical significance, the
difference in magnitude of change over time in creatinine
between the placebo group and the treatment groups were
slightly larger among those with probable kidney disease at
baseline than those without (Table 2 and Figures 2b and 3b).
The interaction of treatment and probable kidney disease at
baseline is significant for both eGFR and serum creatinine
(Po0.01). Results from the kidney-related adverse events
outcome confirm this association. The risk of incident events
related to kidney disease among those with probable kidney
disease at baseline was further reduced by treatment with
raloxifene (relative hazard (95% CI) 0.27 (0.12–0.59),
P-interaction 0.09).
DISCUSSION
In this post-hoc analysis of a large placebo-controlled, double-
masked randomized clinical trial of raloxifene’s effect on
fractures, we found that participants randomized to ralox-
ifene experienced a slower rise of serum creatinine and slower
fall of eGFR compared with the placebo group. Although the
changes in serum creatinine and eGFR were very small over
the course of the trial, these were generally healthy women
who would not be expected to have large decrements in
kidney function over the course of 3 years. This is the first
large study to test this hypothesis and to show a potential
kidney protective effect of raloxifene in humans. In addition,
as in a previous analysis of the MORE data, our analysis
shows no marked difference in kidney-specific safety for
patients with and without kidney disease on raloxifene
treatment.18
We do not know why there was a difference in treatment
effects seen between years 0–3 and year 4. Other analyses of
the MORE data for other outcomes did not see a difference
between the two phases.19 One may conjecture that the
women who continued to the extension were healthier and,
therefore, less likely to experience rises in serum creatinine,
and, therefore, it was even less likely an effect could be seen.
Alternatively, there may be an interaction between the effect
of raloxifene and medications started (such as bispho-
sphonates) or discontinued (such as calcium and vitamin
D) during the extension phase.
There is one small study in humans that suggests that
raloxifene may have beneficial effects on kidney function.20
In this study, 39 post-menopausal women with type 2
diabetes mellitus and albuminuria were randomized to either
raloxifene 60mg or placebo for 6 months. Treatment with
raloxifene was one of the main determinants of absolute
change in the urinary albumin to creatinine ratio. An analysis
of the Nurses’ Health Study revealed that women who used
post-menopausal hormone therapy for more than 6 years had
a lower risk of albuminuria in non-diabetic women.21 We did
not find a difference in the prevalence of dipstick proteinuria,
a less accurate measure of proteinuria, over the 3 years of the
MORE trial.
There is conflicting evidence about whether synthetic
estrogen and estrogen in combination with progesterone
itself affect kidney function and proteinuria with some
studies showing beneficial results,22 some studies showing no
effect23 and some showing detrimental effects.24 However,
these studies did not evaluate the effect of estradiol alone, but
treated patients with various combinations of hormone
therapy. A recent analysis of an administrative database in
Alberta Canada followed 5845 women 466 years old for 2
years and found that women on hormone therapy, mostly
estrogen or combined estrogen and progesterone were more
likely to have a more rapid decline in kidney function, as
measured by MDRD eGFR differences.7 This study differed
from ours in several important ways, including the medica-
tion studied, raloxifene versus estrogen, the study design,
observational versus a randomized controlled clinical trial
and most importantly the results. We found that raloxifene
Table 4 | Association between treatment with raloxifene and 3-year incidence of adverse events related to kidney disease
Raloxifene 60mg/day Raloxifene 120mg/day Pooled raloxifene
Outcome
Placebo
N (%) N (%)
Relative hazard
(95% CI)a N (%)
Relative hazard
(95% CI)a N (%)
Relative hazard
(95% CI)a
Adverse event related to kidney disease 29 (1.13) 10 (0.39) 0.37 (0.18–0.77) 18 (0.70) 0.62 (0.34–1.14) 28 (0.55) 0.50 (0.29–0.85)
Kidney function abnormal 12 (0.47) 4 (0.16) 11 (0.43) 15 (0.29)
Kidney tubular disorder 1 (0.04) 0 0 0
Kidney tubular necrosis 0 1 (0.04) 0 1 (0.02)
Nephritis 2 (0.08) 0 0 0
Nephrosclerosis 1 (0.04) 0 0 0
NPN increased 5 (0.19) 3 (0.12) 1 (0.04) 4 (0.08)
Albuminuria 7 (0.27) 2 (0.08) 1 (0.04) 3 (0.06)
BUN increased 3 (0.12) 1 (0.04) 0 1 (0.02)
Anuria 0 0 1 (0.04) 1 (0.02)
Creatinine clearance decreased 2 (0.08) 0 0 0
Glomerulitis 0 1 (0.04) 3 (0.12) 4 (0.08)
Uremia 2 (0.08) 0 1 (0.04) 1 (0.02)
Uremic coma 0 0 1 (0.04) 1 (0.02)
Abbreviations: BUN, blood urea nitrogen; CI, confidence interval; NPN, non-protein nitrogen.
To convert creatinine to mmol/l multiply by 88.4.
aReference=placebo group.
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treatment overall was associated with a lower rate of eGFR
decline and that in a group with probable kidney disease,
there was no difference in eGFR decline between raloxifene
and placebo, and also no significant change from baseline
eGFRs. The Ahmed analysis found estrogen to be associated
with a loss of kidney function. It may be that SERMs function
differently in the kidney than estrogens, as they do in other
tissues, such as the endometrium.25 Further research is
needed to clarify these very marked differences.
Gender differences in animal models of kidney disease
suggest that female sex hormones may have a function in the
progression of kidney disease. There are numerous animal
models of kidney disease, in which males and post-
menopausal females have more severe disease.9,26 In many
rodent models, hormonal manipulation affects the progres-
sion of kidney disease. Estrogen deficiency by ovariectomy
has been shown to be detrimental and estradiol treatment is
protective in these models of disease.27–31 In a mouse model
of diabetes, the db/db mouse, raloxifene has been shown to
reduce kidney damage.16 Studies of cultured mesangial cells
show that estradiol, tamoxifen, and raloxifene inhibit the
generation of types I and IV collagen,13–15 whereas testoster-
one has no effect.32 In addition to affecting collagen
generation, estrogens have been shown to affect the activity
of two collagen degrading enzymes, metalloproteinase-233
and metalloproteinase-934 in cultured kidney cells. One
potential mechanism by which estrogen affects collagen
generation is by means of TGFb. In cultured mesangial cells,
estradiol inhibits the pro-fibrotic effects of TGFb by
interfering with the activity of casein kinase II35 and in the
TGF-b transgenic mouse, estradiol mitigates the severe
glomerulosclerosis seen.31
Although raloxifene is a SERM and did not cause
increased vaginal bleeding or breast pain during the MORE
trial, it was associated with a increased relative risk of venous
thromboembolism (relative risk (RR): 3.1; 95% CI, 1.5–6.2).36
In another clinical trial of 10,101 post-menopausal women,
raloxifene use was associated with a hazard ratio of 1.44 (95%
CI, 1.06–1.85) for venous thromboembolism and 1.49 (95%
CI, 1.00–2.24) for fatal stroke.37 In that trial, raloxifene use
had no effect on the risk of coronary events (hazard ratio,
0.96, 95% CI, 0.84–1.07), but reduced the risk of invasive
breast cancer (hazard ratio, 0.56, 95% CI, 0.38–0.83).37
Although these risks are present, an analysis of Medicaid
claims from all 50 states showed that there were over 750,000
yearly prescriptions in 2004.38 The potential risks of
raloxifene use must be weighed against any benefits suggested
by this post-hoc analysis and the true effects of raloxifene on
kidney function and albuminuria need to be tested in a
randomized clinical trial evaluating specifically kidney disease
outcomes. We found that the differences between the
treatment groups and placebo are of modest size and suggest
that use of raloxifene is safe from a renal perspective.
There are potential limitations to the current analysis.
Urine proteinuria testing was performed by urine dipstick
that is not as accurate as a urine albumin to creatinine ratio
or a 24 h urine collection and is dependent on urinary
concentration. Because it is not a good measure it would tend
to bias results towards the null hypothesis. Our measurement
of adverse events was limited in that it only consisted of
self-reported events that were not confirmed by chart review.
In addition, the population in the MORE trial was at very low
risk for progression of kidney disease because of low
prevalence of diabetes, albuminuria and advanced kidney
disease, future studies will need to be adequately powered
to evaluate only hard end-points in a population with a
higher risk for progression. The limited number of
participants with diabetes mellitus, proteinuria and on
angiotensin-converting enzyme inhibitors or angiotensin
receptor blockers are baseline also potentially limits the
generalizability of the results. This is a post-hoc analysis and
was not part of the original trial hypotheses; therefore, it may
be appropriate to apply stricter definitions for statistical
significance. However, we present data from a randomized
placebo-controlled double-blinded clinical trial of approxi-
mately 7000 women followed prospectively for 3 years in 25
countries.
In summary, this post-hoc analysis of the MORE trial
looking at kidney disease outcomes revealed that women
randomized to raloxifene experienced a slower increase in
serum creatinine and decline in eGFR compared with their
counterparts on placebo. They also had fewer adverse
events related to kidney disease. These findings should be
confirmed in a large randomized clinical trial in post-
menopausal women with advanced kidney disease and
albuminuria. However, our data can conclude that the use
of raloxifene is safe and is not associated with declines in
kidney function.
METHODS
Design, settings, and participants
The MORE study was a multi-center, randomized, double-masked
clinical trial designed to test whether treatment with raloxifene
reduces the risk of fractures in post-menopausal women with
osteoporosis.36,39 The study, conducted between 1994–1999, enrolled
7705 women at 180 centers in 25 countries.36 A 1-year extension was
added to the 3-year core treatment phase to assess secondary end-
points (cardiovascular disease risk, breast cancer risk). Between years
3 and 4 women were allowed to take any medication their own
physicians ordered, including bisphosphonates or other bone-active
agents, with the exception of oral estrogen or estrogen-progestin
therapy. During this extension phase women continued on
treatment with raloxifene or placebo as initially assigned.
Exclusion criteria of the MORE trial pertinent to the current
analysis included having a creatinine 42.5mg/dl and active
renal lithiasis. There were 722 women without both a baseline and
at least one post-baseline measure of creatinine, which is required
for the current analysis. Therefore, 6933 women are included in the
current analysis (Figure 1). The percentage of participants on
placebo and raloxifene was similar among the women in the analysis
subset and those 722 women not included in the current analysis
(P¼ 0.68). The ethical review board at each site approved the
study and written informed consent was obtained from all
participants.
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Randomization and interventions
Women were stratified by site and randomly assigned to receive
placebo, raloxifene 60 or 120mg/day. The sponsor supplied
randomly numbered kits containing tablets that were identical in
appearance. The women received two tablets daily: two placebo, one
placebo and one tablet of 60mg raloxifene, or two tablets of 60mg
raloxifene. All women in the study also received 500mg of calcium
and 400–600 IU of cholecalciferol daily.36 Participants, investigators,
and laboratory staff were masked to treatment assignment.
Outcomes and follow-up
Serum creatinine was measured in the MORE trial by SciCor
(Covance) Central Laboratory Services (Indianapolis, IN) using the
modified Jaffe reaction. Participants had creatinine measures done
at their original lab at enrollment and annually thereafter. Measures
were also made at the termination visit if the participant did not
complete the trial. eGFR was estimated using the four-variable
standardized Modification of Diet in Renal Disease (MDRD) Study
equation for each serum creatinine value.40 The change over time
in serum creatinine level and eGFR were examined as continuous
outcomes.
At visits that occurred 3 and 6 months after enrollment and every
6 months thereafter, women were asked whether they had
experienced any adverse event since the last visit (any undesirable
experience, including any illness or accidental injury occurring
during the study, whether or not it is considered to be related to the
study drug). These adverse events reported were categorized using
the Coding Symbols and Thesaurus for Adverse Reaction Termino-
logy dictionary,41 but were not independently confirmed by
obtaining verification other than participant report. A physician
blinded to treatment status (MLM) reviewed all adverse events
collected throughout the study and determined those to classify as
an adverse kidney event. For this analysis, adverse events related to
kidney disease included those coded as, ‘Kidney function abnormal,
kidney tubular disorder, kidney tubular necrosis, nephritis, nephro-
sclerosis, non-protein nitrogen increased, blood urea nitrogen
increased, albuminuria, anuria, creatinine clearance decreased,
glomerulitis, uremia, and uremic coma.’ Excluded were any adverse
events coded as ‘acute renal failure, kidney cortex necrosis,
nephrosis, oliguria, polycystic kidney, toxic nephropathy, dehydra-
tion, hematuria, and hydronephrosis’. These were excluded as they
may represent either acute processes or structural abnormalities, not
necessarily associated with progressive kidney disease. Adverse
kidney events were compared between the raloxifene and placebo
groups as a secondary analysis.
Another secondary outcome was proteinuria, which was
measured by semiquantitative urine dipstick using IRIStrips (Roche
Diagnostics, Indianapolis, IN). Proteinuria was defined in this
analysis as anyone who had a protein dipstick of 1þ or greater.
Proteinuria was measured at baseline, annually and at the
termination visit if the participant did not complete the trial.
Other measurements
Baseline information regarding age, race, menstrual history,
smoking status and health conditions was gathered using a
questionnaire. Baseline clinical assessments included height, weight,
blood pressure, measurement of serum lipids, hemoglobin A1C and
fasting blood glucose. Use of all current prescription and other
medication was recorded. Hypertension for this analysis was defined
as having a blood pressure X140/90mmHg, self-reported hyper-
tensive status or the use of anti-hypertensive medications at
baseline. Diabetes mellitus was defined as having the fasting blood
glucose of X126mg/dl, self-reported diabetic status or the use of
hypoglycemic medications at baseline (to convert to mmol/l
multiply by 0.0555). Serum estradiol was measured at baseline by
SciCor (Covance) central laboratory services using a double
antibody assay process. Serum estradiol concentrations were
categorized as o1.4 pg/ml (too low to detect) and X1.4 pg/ml
(to convert to pmol/l multiply by 3.671).
Statistical analysis
Baseline participant characteristics were compared across the three
treatment groups using the w2-test for categorical data, and analysis
of variance for normally distributed continuous data and Kruskal–-
Wallis tests for skewed continuous data.
Characteristics among those women who elected to continue for
the year 3–4 extension phase of the trial could be different among
treatment and placebo groups resulting from discontinuations. Also,
the use of other bone-active agents was allowed during this
extension phase. These factors may lead to differing treatment
effects on our outcomes during years 0–3 and the year 3–4 extension
period (phase of study). The potential differences in characteristics
were compared between those who stopped at or before year 3 and
those who continued on to the year 3–4 extension using w2-tests
for categorical data, Student’s t-tests for normally distributed
continuous data and Wilcoxon rank-sum tests for skewed
continuous data. For the primary outcomes of creatinine and eGFR,
analysis was performed to examine whether there was a significant
interaction between treatment and phase of the study. Annualized
percent change in creatinine and eGFR were examined using a
generalized linear model with independent variables for treatment
group and phase, plus the interaction of these two variables. If an
interaction between treatment and study phase was significant then
the treatment effect on our outcomes during the 1-year extension
phase would be considered to be different from the core treatment
phase, and subsequent analyses would focus on the core treatment
phase.19
Random-effects models were used to analyze the association
between the treatment effect and the change in serum creatinine
level and eGFR. These models account for between-participant
variation and within-participant correlation of repeated outcomes.42
The random effect terms included both the intercept and the slope
of the measurements over time, allowing for individual time trends
for each participant. Variances and covariances were estimated using
the restricted maximum likelihood method. Time was modeled as a
continuous covariate, measured as years from baseline. Mean change
from baseline to year 3 was calculated based on results from the
models.
Any effect of raloxifene on serum creatinine or eGFR may
depend on factors, such as endogenous estradiol levels (X1.4 versus
o1.4 pg/ml) and the presence of hypertension or diabetes. Baseline
kidney function may also affect the relationship between raloxifene
and change in kidney function. Therefore, we created a category
defined as probable kidney disease that included all participants
with an eGFR o45ml/min per 1.73m2, diabetes mellitus,
proteinuria, or use of angiotensin-converting enzyme inhibitors or
angiotensin receptor blockers at baseline. Secondary analyses
examining the effects of raloxifene treatment within strata of these
selected baseline factors, was also performed. Additional random-
effects models with added terms for the strata plus the interaction of
strata and treatment were performed. A model adjusting for any
baseline covariates associated with treatment was performed, to see
Kidney International (2011) 79, 241–249 247
ML Melamed et al.: Raloxifene and kidney function o r ig ina l a r t i c l e
whether this explained the observed effects of raloxifene. In
addition, because blood pressure can affect kidney function and
proteinuria, we performed another sensitivity analysis adjusting for
achieved blood pressure as a time-varying covariate, to evaluate
whether the effects of raloxifene on kidney function may be
mediated through effects on blood pressure. Similar analyses were
performed with the time-varying covariates of low-density lipopro-
tein cholesterol and hemoglobin A1C. These analyses were limited to
women at the 14 study sites where follow-up measures of low-
density lipoprotein cholesterol (n¼ 2378) and hemoglobin A1C
(n¼ 2615) were performed.
The secondary outcome of incident kidney-related adverse events
was analyzed using a proportional hazards model. The secondary
outcome of the presence of proteinuria was analyzed using a
longitudinal analysis based on data from all baseline and all post-
baseline time points. Generalized estimating equations were
preformed with terms for treatment, years from baseline, and an
interaction term between the time and treatment to test the
hypothesis that the rate of change of proteinuria over time differed
among treatment groups.
All statistical analyses were performed using SAS version 9.1
(SAS Institute, Cary, NC). Statistical significance was set at a two-
sided P-value of o0.05.
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